Using SGLT2-inhibitors to treat cardiac patients with diabetes

Sdílet
Vložit
  • čas přidán 13. 11. 2018
  • At our 2018 symposium, "Management of Type 2 Diabetes in Patients with CVD: Focus on Heart Failure," nephrologist and scientist Dr. David Cherney explores the use of SGLT2-inhibitors in cardiovascular and renal protection.

Komentáře • 14

  • @RM-hq7wn
    @RM-hq7wn Před 5 měsíci

    Very nice 👍

  • @RoshanLovesall
    @RoshanLovesall Před 3 lety

    Beautiful explaination. Continue the good work

  • @bishopecart
    @bishopecart Před 3 lety

    Awesome study as it relates to HFrEF

  • @mattiaslarsson4085
    @mattiaslarsson4085 Před 2 lety

    Great!

  • @ahmedahm1
    @ahmedahm1 Před 2 lety

    2:42 Good explanation ! So can patients with prediabetes and microalbuminuria take SGLT2i ?

  • @adrienmonk2469
    @adrienmonk2469 Před 2 lety

    Im sorru sir , but the is not a cotransporter Na /K /2Cl in the distal tubel lumen .
    you heve to corrcte that .

  • @lexus0077
    @lexus0077 Před 11 měsíci

    SGLT 2 ??? ,What is this ?

  • @oswaldfernandes8266
    @oswaldfernandes8266 Před 3 lety +1

    Statistical analysis of covid deaths in diabetics on sglt2 inhibitors will provide the answer

  • @oswaldfernandes8266
    @oswaldfernandes8266 Před 3 lety +2

    The drug is a killer in diabetic covid patients. This fact outweighs the benefits of the drug in view of the pandemic as I have lost my brother Simon because of sglt2 inhibitors